Form 4: Indaptus Therapeutics COO Acquires Stock Options
SEC Form 4
Walt Addison Linscott, Chief Operating Officer of Indaptus Therapeutics, Inc., acquired stock options for 75,000 shares on October 9, 2024.
Summary
- On October 9, 2024, Walt Addison Linscott, the Chief Operating Officer of Indaptus Therapeutics, Inc. (INDP), acquired stock options.
- The stock options grant him the right to buy 75,000 shares of common stock at an exercise price of $1.105 per share.
- The options vest fully on April 9, 2026, contingent upon Mr. Linscott's continued service to the company.
Sentiment
Score: 6
Explanation: The document reflects a routine executive compensation event. It's neutral to slightly positive as it indicates continued alignment of the COO with the company's long-term success.
Future Outlook
The vesting of the options is contingent upon the Reporting Person's continued service to the Issuer through the vesting date.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's value.
Stakeholder Impact
- The stock option grant aligns the COO's interests with those of shareholders, potentially leading to increased company value.
Key Dates
| Date | Description |
|---|---|
| 10/09/2024 | Date of stock option grant |
| 10/09/2024 | Date of earliest transaction |
| 04/09/2026 | Stock options vest and become exercisable in full |
| 10/09/2034 | Expiration date of the stock options |
| 10/10/2024 | Date of signature |
Keywords
stock options, Form 4, INDP, Indaptus Therapeutics, Walt Linscott, COO, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.